Dezhan Healthcare Company (000813) Fair Value & Analysis
Healthcare · CN · Market cap 6.5B CNY
Fair value as of: Jul 21, 2026
From 1 valuation models · updated today
Fair value updated Jul 21, 2026, revised from ¥9.95 to ¥1.11 (−88.8%) since Jun 25, 2026. Share price +10.8% over the past month.
Price vs Fair Value (12 months)
12‑month range ¥2.90 – ¥4.85 · fair‑value band ¥0.7300 – ¥1.39 · the ¥3.29 price screens above the ¥1.11 fair value. As of Jul 21, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Dezhan Healthcare Company (000813) currently trades at ¥3.29, while our model-based Fair Value estimate is ¥1.11, implying the stock looks roughly 66.3% overvalued today. We read business quality at 41/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Dezhan Healthcare Company generated revenue of 396M CNY at a net margin of -90.3%. Revenue declined 0.7% year over year. It earns a return on equity of -9.0%. The balance sheet holds a net cash position of 2.5B CNY. Fundamentals as of Jul 21, 2026
Our scenario range runs from ¥0.7300 (bear case) to ¥1.39 (bull case); at ¥3.29, the current price sits above that range. The share trades about 37% below its 52-week high and 11% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -66%, 000813 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 21, 2026. TTM = trailing twelve months.
About the company
Dezhan Healthcare Company Limited engages in the research and development, manufacture, and sale of cardiovascular and cerebrovascular drugs in the People's Republic of China. The company offers atorvastatin calcium tablets, amlodipine atorvastatin calcium tablets, trimetazidine hydrochloride capsules, amiodarone hydrochloride tablets, as well as other drugs, including famciclovir tablets, azathioprine tablets, and hydroxyurea tablets and colchicine tablet. It also involved in the provision of biological peptides, industrial hemp, and medical service business. The company was founded in 1980 and is based in Beijing, the People's Republic of China.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Dezhan Healthcare Company reported revenue of ¥397M in FY2025 versus ¥734M in FY2021, a compound −14.3%/yr. Reported net income was −¥345M in FY2025.
Is 000813 fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥49.36 | ¥30.99 | -37% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| PharmaEssentia Corporation 6446 | 1,095 TWD | 365.87 TWD | -67% |
| Cipla Limited CIPLA | ₹1,401 | ₹592.37 | -58% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Lupin Limited LUPIN | ₹2,268 | ₹2,697 | +19% |
| Mankind Pharma Limited MANKIND | ₹2,336 | ₹1,068 | -54% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Dezhan Healthcare Company (000813) undervalued?
What is the fair value of 000813?
What is the quality score of 000813?
What is the revenue of Dezhan Healthcare Company (000813)?
What is the net profit margin of 000813?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Tell me when Dezhan Healthcare Company reaches its Fair Value
Just your email, and we'll notify you when the price and Fair Value of Dezhan Healthcare Company materially change. Free bonus: the monthly Top-25 report of the most undervalued quality stocks.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.